Read our submission to the Standing Committee on Finance of Canada in advance of budget 2019:
Congratulations to Geoffrey Hinton (University of Toronto), Joshua Bengio (Université de Montréal) and Yann LeCun (Boston University) who have won the 2019 Turing award for their work to understand neural networks using artificial intelligence and deep learning. The Turing Award is an annual prize given by the Association for Computing Machinery (ACM) to an individual selected for contributions “of lasting and major technical importance to the computer field”. The award is accompanied by a $1 million USD prize, to be shared by the three winners.
Read more on the Association for Computing Machinery website
Fathers of the Deep Learning Revolution Receive ACM A.M. Turing Award
Bengio, Hinton and LeCun Ushered in Major Breakthroughs in Artificial Intelligence
Geoffrey Hinton will be present at the CAN meeting on May 21, 2019, where he will present the CAN annual public lecture, which will be hosted by Blake Richards, from the University of Toronto. More here.
New therapeutic molecules developed at Toronto’s Centre for Addiction and Mental Health (CAMH) show promise in reversing the memory loss linked to depression and aging.
These molecules not only rapidly improve symptoms, but remarkably, also appear to renew the underlying brain impairments causing memory loss in preclinical models. These findings were presented at the American Association for the Advancement of Science (AAAS) Annual Meeting in Washington DC.
“Currently there are no medications to treat cognitive symptoms such as memory loss that occur in depression, other mental illnesses and aging,” says Dr. Etienne Sibille, Deputy Director of the Campbell Family Mental Health Research Institute at CAMH and lead scientist on the study.
The Brain Prize 2019: French neuroscientists honoured for outstanding research into small vessel strokes in the brain
Aiming for treatment they have spent more than 30 years describing, understanding and diagnosing the most common hereditary form of stroke, CADASIL. For this, the four French neuroscientists are now receiving the world’s most valuable prize for brain research – the Lundbeck Foundation Brain Prize, worth 1 million euros.
Jean-Pierre Julien’s team recently published an article in the high impact journal, the Journal of Clinical Investigations, about a new experimental therapy for ALS and frontotemporal dementia based on the use of antibodies that target the abnormal accumulation of a protein called TDP-43 in degenerating neurons. The formation of TDP-43 aggregates is associated with ALS development.
We often think of our brains as the centre of complex motor function and control, but how ‘smart’ is your spinal cord? Turns out, it is smarter than we think.
Circuits which travel down the length of our spine control things like the pain reflex in humans and some motor-control functions in animals. Now, new research from Western has shown that the spinal cord is also able to process and control more complex functions, like the positioning of your hand in external space.
Researchers at Western have developed an objective way to monitor female athletes’ concussion injury, by using brain scans to study their brains over time.
By using a technique that combines both structural and functional MRI information, Western University researchers were able to identify three unique signatures – one that shows acute brain changes after an athlete has suffered a concussion, another that can identify persistent brain changes six months after the concussion and a third that shows evidence of concussion history.
Queen’s University researcher discovers potential new treatment for Alzheimer’s disease.
Queen’s University researcher Fernanda De Felice (Psychiatry), along with co-authors from the Federal University of Rio de Janeiro, have identified an exercise-linked hormone that could slow the progression of Alzheimer’s disease. This research was recently published in the high-profile publication, Nature Medicine.
Scientists find a new application for an existing drug, with potential to slow progression of the devastating degenerative disease.
A drug typically used to treat hepatitis could slow the progression of ALS, also known as Lou Gehrig’s disease, according to new research by University of Alberta scientists.
Ghrelin promotes conditioning to food-related odours
The holiday season is a hard one for anyone watching their weight. The sights and smells of food are hard to resist. One factor in this hunger response is a hormone found in the stomach that makes us more vulnerable to tasty food smells, encouraging overeating and obesity. New research on the hormone ghrelin was published on Dec. 4, 2018, led by Dr. Alain Dagher’s lab at the Montreal Neurological Institute and Hospital of McGill University.